The US Food and Drug Administration (FDA) has seen enough from PharmaMar (MSE: PHM) to accept a filing for an accelerated approval for lurbinectedin monotherapy as a treatment second-line small cell lung cancer (SCLC).
PharmaMar is a Spanish company that claims to be the world leader in the development and commercialization of oncology drugs of marine origin.
The company anticipates that the New Drug Application (NDA) filing for lurbinectedin will take place in the fourth quarter of 2019.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze